Net Loss Per Share - Schedule of Antidilutive Securities, Excluded from Computation of Diluted Net Loss per Share (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Net Loss Per Share | ||
| Dilutive impact from potentially issuable common shares | $ 0 | $ 0 |
| Total common stock equivalents | 32,633,128 | 27,650,467 |
| Pre-Funded Warrants | ||
| Net Loss Per Share | ||
| Warrants outstanding | 5,818,592 | 10,805,957 |
| Options to purchase common stock | ||
| Net Loss Per Share | ||
| Total common stock equivalents | 26,357,791 | 21,182,163 |
| RSUs | ||
| Net Loss Per Share | ||
| Total common stock equivalents | 4,775,337 | 4,968,304 |
| PSUs | ||
| Net Loss Per Share | ||
| Total common stock equivalents | 1,500,000 | 1,500,000 |